Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00201409 · ClinicalTrials.gov registry record · Phase 2
A Randomized Trial of GM-CSF in Patients With ALI/ARDS
A Phase 2 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
NCT00201409 is a Phase 2 study that has completed, run by University of Michigan. The registered enrollment target is 132 participants.
The verdict
NCT00201409, a Phase 2 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
Study Summary
This study will test the hypothesis that administration of granulocyte-macrophage colony stimulating factor (GM-CSF) to patients with acute lung injury/acute respiratory distress syndrome (ALI/ARDS) will improve the clinical course and outcome by shortening the duration of mechanical ventilation for these patients.
Interventions
- DRUG Placebo
- DRUG GM-CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2004-07 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00201409
The ClinicalTrials.gov registry entry for NCT00201409 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00201409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00201409 about?
NCT00201409 is a clinical study titled "A Randomized Trial of GM-CSF in Patients With ALI/ARDS". This study will test the hypothesis that administration of granulocyte-macrophage colony stimulating factor (GM-CSF) to patients with acute lung injury/acute respiratory distress syndrome (ALI/ARDS) will improve the clinical course and outcome by shortening the duration of mechanical ventilation for...
What is the current status of trial NCT00201409?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2004-07. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00201409?
The interventions under investigation include: Placebo (DRUG), GM-CSF (DRUG).
Who is sponsoring clinical trial NCT00201409?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.